A5061135039- Immune Cell Function and Interaction
- CAR-T cell therapy research
- Cancer Cells and Metastasis
- T-cell and B-cell Immunology
- Cancer Research and Treatments
- Genetic factors in colorectal cancer
- Prostate Cancer Treatment and Research
- Acute Myeloid Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Monoclonal and Polyclonal Antibodies Research
- Lymphoma Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Chronic Lymphocytic Leukemia Research
- Wnt/β-catenin signaling in development and cancer
- Complement system in diseases
- Glycosylation and Glycoproteins Research
- COVID-19 Clinical Research Studies
- Digestive system and related health
- IL-33, ST2, and ILC Pathways
- Immunotherapy and Immune Responses
- Toxin Mechanisms and Immunotoxins
- Galectins and Cancer Biology
- SARS-CoV-2 and COVID-19 Research
Innate Pharma (France)
2018-2024
Eurobio (France)
2017
Centre National de la Recherche Scientifique
2012
Université Claude Bernard Lyon 1
2012
Coronavirus disease 2019 (COVID-19) is a caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and has resulted in pandemic1. The C5a complement factor its receptor C5aR1 (also known as CD88) have key role the initiation maintenance of several inflammatory responses recruiting activating neutrophils monocytes1. Here we provide longitudinal analysis immune responses, including phenotypic analyses cells assessments soluble factors that are present blood...
Harnessing innate immunity is emerging as a promising therapeutic approach in cancer. We report here the design of tetraspecific molecules engaging natural killer (NK) cell-activating receptors NKp46 and CD16a, β-chain interleukin-2 receptor (IL-2R), tumor-associated antigen (TAA). In vitro, these antibody-based cell engager therapeutics (ANKETs) induce preferential activation proliferation NK cells, binding to targeted TAA triggers cytotoxicity cytokine chemokine production. vivo, ANKETs...
NK cells offer a promising alternative to T cell therapies in cancer. We evaluated IPH6501, clinical-stage, tetraspecific engager (NKCE) armed with non-alpha IL-2 variant (IL-2v), which targets CD20 and was developed for treating B non-Hodgkin lymphoma (B-NHL). CD20-NKCE-IL2v boosts proliferation cytotoxicity, showing activity against range of B-NHL lines, including those low density. Whereas it presented reduced toxicities compared commonly associated therapies, showed greater killing...
Purpose: Patients with metastatic colorectal cancer suffer from disease relapse mainly due to stem cells (CSC). Interestingly, they have an increased level of blood progastrin, a tumor-promoting peptide essential for the self-renewal colon CSCs, which is also direct β-catenin/TCF4 target gene. In this study, we aimed develop novel targeted therapy neutralize secreted progastrin inhibit Wnt signaling, and reduce relapses.Experimental Design: Antibodies (monoclonal humanized) directed against...
Abstract Background: Nectin-4 is a cell membrane adhesion protein overexpressed in several solid tumors, including urothelial, breast, lung, ovarian, and pancreatic cancers, with limited expression normal tissues, making it an ideal target for antibody-drug conjugates (ADC). Enfortumab Vedotin (EV, PADCEV®) ADC targeting monomethyl auristatin E (MMAE) payload approved the treatment of patients urothelial carcinoma (UC), but clinical activity reported beyond UC. In addition, EV causes...
Abstract Inhibitory CD94-NKG2A (Natural Killer Group 2A) receptors are expressed on subsets of natural killer (NK) cells, γδ and CD8+ T cells. HLA-E (Human Leukocytes Antigen-E), the ligand for CD94-NKG2A, is upregulated cancer cells several solid tumors, providing a negative regulatory signal to tumor-infiltrating lymphocytes (TILs). Blockade this immune checkpoint pathway with anti-NKG2A monoclonal antibodies (Ab) enhances NK cell responses tumor in vitro humanized mice. Here, we describe...
<h3>Background</h3> Most immunomodulatory approaches have focused on enhancing T-cell responses, with immune checkpoint inhibitors, chimeric antigen receptor T cells or bispecific antibodies. Although these therapies led to exceptional successes, only a minority of cancer patients benefit from treatments, highlighting the need identify new and molecules that could be exploited in next generation immunotherapy. Given crucial role innate responses immunity, harnessing opens up possibilities...
<p>Contain all the supplementary methods linked to this paper</p>
<p>Contain all the supplementary methods linked to this paper</p>
<div>Abstract<p><b>Purpose:</b> Patients with metastatic colorectal cancer suffer from disease relapse mainly due to stem cells (CSC). Interestingly, they have an increased level of blood progastrin, a tumor-promoting peptide essential for the self-renewal colon CSCs, which is also direct β-catenin/TCF4 target gene. In this study, we aimed develop novel targeted therapy neutralize secreted progastrin inhibit Wnt signaling, and reduce...
<div>Abstract<p><b>Purpose:</b> Patients with metastatic colorectal cancer suffer from disease relapse mainly due to stem cells (CSC). Interestingly, they have an increased level of blood progastrin, a tumor-promoting peptide essential for the self-renewal colon CSCs, which is also direct β-catenin/TCF4 target gene. In this study, we aimed develop novel targeted therapy neutralize secreted progastrin inhibit Wnt signaling, and reduce...
Background: CD20 is strongly and homogeneously expressed on all mature B-cells the majority of B-cell neoplasms. Despite several generations CD20-targeting drugs including rituximab, ofatumumab, obinutuzumab, more recent approvals new agents, innovative strategies are still needed for B-NHL patients who relapse or refractory (R/R) after multiple lines treatment. Recently, clinical responses following CAR-NK cell infusions without major toxic effects were observed in R/R with hematologic...